Literature DB >> 21559924

[Radiological diagnostics of ovarian cancer].

M Meissnitzer1, R Forstner.   

Abstract

Ovarian cancer is diagnosed in stages FIGO III/IV in up to 75% of cases. Despite medical advances the 5-year survival rate has only been moderately increased to 44% during recent years. The initial evaluation is performed using transvaginal ultrasound (US) (sensitivity 90-96%, specificity 98-99% for detection of ovarian lesions). Probably benign findings will be followed-up sonographically or will be laparoscopically excised. Magnetic resonance imaging (MRI) allows a definitive diagnosis in more than 90% of sonographically indeterminate lesions. Malignant lesions require computer tomography (CT) staging and treatment in gynecology centers in a multidisciplinary setting. Peritoneal implants larger than 1 cm are detected equally by CT and MRI. Detection of ascites which is associated with peritoneal carcinomatosis in up to 80% of cases is equally feasible by US, CT and MRI.

Entities:  

Mesh:

Year:  2011        PMID: 21559924     DOI: 10.1007/s00117-010-2120-8

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  24 in total

1.  A multidisciplinary approach to ovarian cancer at diagnosis.

Authors:  J A Spencer
Journal:  Br J Radiol       Date:  2005       Impact factor: 3.039

2.  Adnexal masses: accuracy of detection and differentiation with multidetector computed tomography.

Authors:  A C Tsili; C Tsampoulas; A Charisiadi; John Kalef-Ezra; V Dousias; E Paraskevaidis; S C Efremidis
Journal:  Gynecol Oncol       Date:  2008-05-16       Impact factor: 5.482

3.  Characterization of complex adnexal masses: value of adding perfusion- and diffusion-weighted MR imaging to conventional MR imaging.

Authors:  Isabelle Thomassin-Naggara; Irwin Toussaint; Nicolas Perrot; Roman Rouzier; Charles A Cuenod; Marc Bazot; Emile Daraï
Journal:  Radiology       Date:  2010-12-30       Impact factor: 11.105

4.  Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study.

Authors:  P Hoskins; E Eisenhauer; I Vergote; J Dubuc-Lissoir; B Fisher; R Grimshaw; A Oza; M Plante; G Stuart; J Vermorken
Journal:  J Clin Oncol       Date:  2000-12-15       Impact factor: 44.544

5.  MRI of sonographically indeterminate adnexal masses.

Authors:  Saroja Adusumilli; Hero K Hussain; Elaine M Caoili; William J Weadock; John P Murray; Timothy D Johnson; Qixuan Chen; Benoit Desjardins
Journal:  AJR Am J Roentgenol       Date:  2006-09       Impact factor: 3.959

6.  Development of an ovarian cancer symptom index: possibilities for earlier detection.

Authors:  Barbara A Goff; Lynn S Mandel; Charles W Drescher; Nicole Urban; Shirley Gough; Kristi M Schurman; Joshua Patras; Barry S Mahony; M Robyn Andersen
Journal:  Cancer       Date:  2007-01-15       Impact factor: 6.860

7.  Survival and prognostic factors in patients with ovarian cancer.

Authors:  Solveig Tingulstad; Finn Egil Skjeldestad; Tore B Halvorsen; Bjørn Hagen
Journal:  Obstet Gynecol       Date:  2003-05       Impact factor: 7.661

8.  Image-guided biopsy in patients with suspected ovarian carcinoma: a safe and effective technique?

Authors:  Nyree Griffin; Lee A Grant; Susan J Freeman; Mercedes Jimenez-Linan; Laurence H Berman; Helena Earl; Ahmed Ashour Ahmed; Robin Crawford; James Brenton; Evis Sala
Journal:  Eur Radiol       Date:  2008-08-15       Impact factor: 5.315

Review 9.  Staging ovarian cancer: role of imaging.

Authors:  Fergus V Coakley
Journal:  Radiol Clin North Am       Date:  2002-05       Impact factor: 2.303

10.  Influence of selected hormonal and lifestyle factors on familial propensity to ovarian cancer.

Authors:  Alessandra Tavani; Cristina Bosetti; Luigino Dal Maso; Laura Giordano; Silvia Franceschi; Carlo La Vecchia
Journal:  Gynecol Oncol       Date:  2004-03       Impact factor: 5.482

View more
  2 in total

1.  HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma.

Authors:  Cecilia Midulla; Lucia Manganaro; Flavia Longo; Valentina Viggiani; Luigi Frati; Teresa Granato; Emanuela Anastasi
Journal:  Tumour Biol       Date:  2012-03-20

2.  [Gynecological tumors of the true pelvis: Radiological diagnosis for pelvic tumors made simple].

Authors:  M Meissnitzer; T Meissnitzer; R Forstner
Journal:  Radiologe       Date:  2015-12       Impact factor: 0.635

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.